前列腺周围水凝胶间隔物辅助的前列腺癌立体定向体部放疗:毒性和早期肿瘤学结局
BACKGROUND: Multiple phase I-II clinical trials have reported on the efficacy and safety of prostate stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer.…
要点
- SpaceOAR间隔物置入后行前列腺SBRT,无≥3级泌尿生殖或胃肠道毒性。
- 治疗期间30%出现新发2级泌尿生殖毒性,1年时降至12%。
- 胃肠道毒性以1级为主,所有症状在1个月内消退,无晚期直肠毒性。
核心结论
- 前列腺周围水凝胶间隔物置入后行SBRT,胃肠道毒性极小,早期肿瘤学结局良好,是低中危局限期前列腺癌耐受性好、安全且方便的治疗选择。
研究设计与样本
- 所有患者置入SpaceOAR水凝胶和基准标记后行治疗前MRI,治疗期间至少每周评估毒性,治疗后1个月及此后每次随访评估,SBRT后4个月起每3-6个月检测PSA。
主要发现
- 20个月时中位PSA为0.9 ng/mL,接受ADT者中位PSA为0.08 ng/mL,未接受ADT者为1.32 ng/mL。
- SpaceOAR在前列腺中部实现的前列腺-直肠平均间隔为9.6 ± 4 mm。
- 无≥3级泌尿生殖或胃肠道毒性记录;治疗期间30%出现新发2级泌尿生殖毒性(尿急或排尿困难),治疗后1个月为30%,1年时为12%。
- 治疗期间胃肠道毒性限于1级症状(16%),SBRT后前4周有4%出现2级症状,所有胃肠道症状在治疗后1个月评估时消退,治疗后1个月以上无急性或晚期直肠毒性报告。
关键数值与推荐
- SBRT剂量方案为3625 cGy分5次。
- 急性毒性按RTOG标准记录。
临床怎么用
- 对低中危局限期前列腺癌患者,可考虑置入前列腺周围水凝胶间隔物后行5次SBRT,以降低直肠毒性并耐受良好。
- 治疗期间及治疗后1年内需关注泌尿生殖毒性(尿急、排尿困难),但多为2级且随时间缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple phase I-II clinical trials have reported on the efficacy and safety of prostate stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer. However, few have reported outcomes for prostate SBRT using periprostatic hydrogel spacer (SpaceOAR; Augmenix). Herein, we report safety and efficacy outcomes from our institutional prostate SBRT experience with SpaceOAR placement. METHODS: Fifty men with low- or intermediate-risk prostate cancer treated at a single institution with linear accelerator-based SBRT to 3625 cGy in 5 fractions, with or without androgen deprivation therapy (ADT) were included. All patients underwent SpaceOAR and fiducial marker placement followed by pre-treatment MRI. Toxicity assessments were conducted at least weekly while on treatment, 1 month after treatment, and every follow-up visit thereafter. Post-treatment PSA measurements were obtained 4 months after SBRT, followed by every 3-6 months thereafter. Acute toxicity was documented per RTOG criteria. RESULTS: Median follow up time was 20 (range 4-44) months. Median PSA at time of diagnosis was 7.4 (2.7-19.5) ng/ml. Eighteen men received 6 months of ADT for unfavorable intermediate risk disease. No PSA failures were recorded. Median PSA was 0.9 ng/mL at 20 months; 0.08 and 1.32 ng/mL in men who did and did not receive ADT, respectively. Mean prostate-rectum separation achieved with SpaceOAR was 9.6 ± 4 mm at the prostate midgland. No grade ≥ 3 GU or GI toxicity was recorded. During treatment, 30% of men developed new grade 2 GU toxicity (urgency or dysuria). These symptoms were present in 30% of men at 1 month and in 12% of men at 1 year post-treatment. During treatment, GI toxicity was limited to grade 1 symptoms (16%), although 4% of men developed grade 2 symptoms during the first 4 weeks after SBRT. All GI symptoms were resolving by the 1 month post-treatment assessment and no acute or late rectal toxicity was reported > 1 month after treatment. CONCLUSIONS: Periprostatic hydrogel placement followed by prostate SBRT resulted in minimal GI toxicity, and favorable early oncologic outcomes. These results indicate that SBRT with periprostatic spacer is a well-tolerated, safe, and convenient treatment option for localized prostate cancer.
引用
- Hwang ME, Mayeda M, Liz M, et al. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes. Radiat Oncol. 2019. PMID: 31375119. doi:10.1186/s13014-019-1346-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。